Paternina-Caicedo A., Quevedo DS., Ríos DS., Moyano D., Alvis-Guzmán N., Alviz-Zakzuk NR., Salcedo F., Moyano L., Ramírez-Suarez J., Smith AD., De la Hoz-Restrepo F.

OBJECTIVE: We carried out a study to estimate the vaccine effectiveness (VE) of homologous vaccination schedules against COVID-19, using data from mandatory information systems from Bogota, Colombia. METHODS: A test-negative case-control study in adults from Bogota (Colombia), between March 1st of 2021 and February 25th of 2022. We assess VE among symptomatic COVID-19 cases during the Mul, Delta, and Omicron predominance periods in Bogota, with controls matched by sex, age (±5 years), and date of testing (±7 days), using a case:control ratio of 1:1. We selected homologous vaccination schedules with ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S. VE was reported as one minus the odds ratio in adjusted conditional logistic regressions, with their 95% confidence intervals (CI). A p-value

Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.

Paternina-Caicedo A., Quevedo DS., Ríos DS., Moyano D., Alvis-Guzmán N., Alviz-Zakzuk NR., Salcedo F., Moyano L., Ramírez-Suarez J., Smith AD., De la Hoz-Restrepo F.

DOI

Type

Journal

Publication Date

Keywords